Dilyara Safina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dilyara Safina has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Sayar R. Abdulkhakov
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia
2 shared publications - Tatyana Vladimirovna Grigoryeva
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia
2 shared publications A. S Popenko
Research Institute for Physico-Chemical Medicine FMBA of Russia Moscow Russia
1 shared publicationA. V Tyakht
1 shared publication- A.V. Laikov
Uchenye Zapiski Kazanskogo Univ, Kazan, Russia
1 shared publication - Dilyara R. Khusnutdinova
Institute of Fundamental Medicine and Biology, Kazan (Volga Region) Federal University, 420008 Kazan, Russia
1 shared publication
Latest Publications
- Open Access
- 3 February 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (2) , 319
Butyric Acid Supplementation Reduces Changes in the Taxonomic and Functional Composition of Gut Microbiota Caused by H. pylori Eradication Therapy
H. pylori eradication therapy leads to significant changes in the gut microbiome, including influence on the gut microbiome’s functional potential. Probiotics are one of the most studied potential methods for reducing the microbiota-related consequences of antibiotics. However, the beneficial effects of probiotics are still under discussion. In addition, there are some concerns about the safety of probiotics, emphasizing the need for research of other therapeutic interventions. The aim of our study was to evaluate the influence of butyric acid+inulin supplements on gut microbiota changes (the gut microbiota composition, abundance of metabolic pathways, and gut resistome) caused by H. pylori eradication therapy. Materials and methods. Twenty two H. pylori-positive patients, aged 19 to 64 years, were enrolled in the study and randomized into two treatment groups, as follows: (1) ECAB-14 (n = 11), with esomeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, and bismuthate tripotassium dicitrate 240 mg, twice daily, per os, for 14 days, and (2), ECAB-Z-14 (n = 11), with esomeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, and bismuthate tripotassium dicitrate 240 mg, twice daily, along with butyric acid+inulin (Zacofalk), two tablets daily, each containing 250 mg of butyric acid, and 250 mg of inulin, per os, for 14 days. Fecal samples were collected from each subject prior to eradication therapy (time point I), after the end of eradication therapy (time point II), and a month after the end of eradication therapy (time point III). The total DNA from the fecal samples was isolated for whole genome sequencing using the Illumina NextSeq 500 platform. Qualitative and quantitative changes in gut microbiota were assessed, including alpha and beta diversity, functional potential and antibiotic resistance gene profiling. Results. Gut microbiota alpha diversity significantly decreased compared with the baseline immediately after eradication therapy in both treatment groups (ECAB-14 and ECAB-Z-14). This diversity reached its baseline in the ECAB-Z-14 treatment group a month after the end of eradication therapy. However, in the ECAB-14 treatment arm, a reduction in the Shannon index was observed up to a month after the end of H. pylori eradication therapy. Fewer alterations in the gut microbiota functional potential were observed in the ECAB-Z-14 treatment group. The abundance of genes responsible for the metabolic pathway associated with butyrate production decreased only in the ECAB-14 treatment group. The prevalence of antibiotic-resistant genes in the gut microbiota increased significantly in both treatment groups by the end of treatment. However, more severe alterations were noted in the ECAB-14 treatment group. Conclusions. H. pylori eradication therapy leads to taxonomic changes, a reduction in the alpha diversity index, and alterations in the functional potential of the gut microbiota and gut resistome. Taking butyric acid+inulin supplements during H. pylori eradication therapy could help maintain the gut microbiota in its initial state and facilitate its recovery after H. pylori eradication.
- 3 February 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (2) , 319
Open AccessButyric Acid Supplementation Reduces Changes in the Taxonomic and Functional Composition of Gut Microbiota Caused by H. pylori Eradication Therapy
H. pylori eradication therapy leads to significant changes in the gut microbiome, including influence on the gut microbiome’s functional potential. Probiotics are one of the most studied potential methods for reducing the microbiota-related consequences of antibiotics. However, the beneficial effects of probiotics are still under discussion. In addition, there are some concerns about the safety of probiotics, emphasizing the need for research of other therapeutic interventions. The aim of our study was to evaluate the influence of butyric acid+inulin supplements on gut microbiota changes (the gut microbiota composition, abundance of metabolic pathways, and gut resistome) caused by H. pylori eradication therapy. Materials and methods. Twenty two H. pylori-positive patients, aged 19 to 64 years, were enrolled in the study and randomized into two treatment groups, as follows: (1) ECAB-14 (n = 11), with esomeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, and bismuthate tripotassium dicitrate 240 mg, twice daily, per os, for 14 days, and (2), ECAB-Z-14 (n = 11), with esomeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg, and bismuthate tripotassium dicitrate 240 mg, twice daily, along with butyric acid+inulin (Zacofalk), two tablets daily, each containing 250 mg of butyric acid, and 250 mg of inulin, per os, for 14 days. Fecal samples were collected from each subject prior to eradication therapy (time point I), after the end of eradication therapy (time point II), and a month after the end of eradication therapy (time point III). The total DNA from the fecal samples was isolated for whole genome sequencing using the Illumina NextSeq 500 platform. Qualitative and quantitative changes in gut microbiota were assessed, including alpha and beta diversity, functional potential and antibiotic resistance gene profiling. Results. Gut microbiota alpha diversity significantly decreased compared with the baseline immediately after eradication therapy in both treatment groups (ECAB-14 and ECAB-Z-14). This diversity reached its baseline in the ECAB-Z-14 treatment group a month after the end of eradication therapy. However, in the ECAB-14 treatment arm, a reduction in the Shannon index was observed up to a month after the end of H. pylori eradication therapy. Fewer alterations in the gut microbiota functional potential were observed in the ECAB-Z-14 treatment group. The abundance of genes responsible for the metabolic pathway associated with butyrate production decreased only in the ECAB-14 treatment group. The prevalence of antibiotic-resistant genes in the gut microbiota increased significantly in both treatment groups by the end of treatment. However, more severe alterations were noted in the ECAB-14 treatment group. Conclusions. H. pylori eradication therapy leads to taxonomic changes, a reduction in the alpha diversity index, and alterations in the functional potential of the gut microbiota and gut resistome. Taking butyric acid+inulin supplements during H. pylori eradication therapy could help maintain the gut microbiota in its initial state and facilitate its recovery after H. pylori eradication.
- Open Access
- 1 January 2023
- Published by Kazan Federal University in Uchenye Zapiski Kazanskogo Universiteta. Seriya Estestvennye Nauki
- Vol. 165 (2) , 190-203
Insights into the Health Effects of Acrolein and Crotonaldehyde in Russian Smokers Switching from Regular Cigarettes to Heated Tobacco Products
The effects of acrolein and crotonaldehyde on the health of Russian smokers upon switching to heated tobacco product use were analyzed in a five-day randomized clinical trial. The findings suggest that heated tobacco products significantly reduce exposure to these toxicants, with the adverse effects becoming less pronounced in just one day and comparable to complete cessation of smoking. The dynamics of nicotine intake and metabolism in the smokers who switched to heated tobacco products remained stable throughout the study and was similar to that in the group of regular cigarette smokers. Therefore, our study, which has been performed for the first time among the Russian population, shows that smokers switching to heated tobacco products are less exposed to harmful chemicals like acrolein and crotonaldehyde and thus may be protected against some of the negative health effects often associated with regular cigarettes.
- 1 January 2023
- Published by Kazan Federal University in Uchenye Zapiski Kazanskogo Universiteta. Seriya Estestvennye Nauki
- Vol. 165 (2) , 190-203
Open AccessInsights into the Health Effects of Acrolein and Crotonaldehyde in Russian Smokers Switching from Regular Cigarettes to Heated Tobacco Products
The effects of acrolein and crotonaldehyde on the health of Russian smokers upon switching to heated tobacco product use were analyzed in a five-day randomized clinical trial. The findings suggest that heated tobacco products significantly reduce exposure to these toxicants, with the adverse effects becoming less pronounced in just one day and comparable to complete cessation of smoking. The dynamics of nicotine intake and metabolism in the smokers who switched to heated tobacco products remained stable throughout the study and was similar to that in the group of regular cigarette smokers. Therefore, our study, which has been performed for the first time among the Russian population, shows that smokers switching to heated tobacco products are less exposed to harmful chemicals like acrolein and crotonaldehyde and thus may be protected against some of the negative health effects often associated with regular cigarettes.
- Open Access
- 15 September 2014
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 9 (3) , 248-252
H. pylori, mikrobiota kishechnika, antibiotikorezistentnost': est' li vzaimosvyaz'?
Helicobacter pylori (H. pylori) eradication is obligatory in case of such diseases as gastric and duodenal ulcer, atrophic gastritis, MALT lymphoma, in patients after gastrectomy due to the gastric cancer, as well as in close relatives of gastric canсer patients. Antibacterial therapy which is aimed at the eradication of H. pylori has an impact on the intestinal microbiotа leading to its qualitative and quantitative disturbances. The review focuses on the influence of H. pylori and eradication therapy on the content of the intestinal microbiota, their role in the development of intestinal microbiota resistance to antibiotics. Both H. pylori itself and eradication therapy can lead to the changes of gut microbiota content, which are characterized by reduction in microorganisms diversity; decrease in the number of obligate anaerobes, prevailing in normal gut; increase in the number of facultative aerobic microorganisms. Long-term effect of antibiotic therapy is the development of antibiotic-resistant strains of bacteria. Resistance may be due to the presence of the resistance genes in bacteria, which they have acquired through mutations or horizontal transfer. These genes can be spread not only among pathogenic bacteria, due to the presence of which antibacterial therapy is carried out, but also among the members of the normal microflora, which can then be modified and loose its beneficial properties. Thus the intestinal microflora may serve as a potential reservoir of resistance genes and contribute to the development of antibiotics resistance through other members of the human microbiota.
- 15 September 2014
- Published by ECO-Vector LLC in Genes & Cells
- Vol. 9 (3) , 248-252
Open AccessH. pylori, mikrobiota kishechnika, antibiotikorezistentnost': est' li vzaimosvyaz'?
Helicobacter pylori (H. pylori) eradication is obligatory in case of such diseases as gastric and duodenal ulcer, atrophic gastritis, MALT lymphoma, in patients after gastrectomy due to the gastric cancer, as well as in close relatives of gastric canсer patients. Antibacterial therapy which is aimed at the eradication of H. pylori has an impact on the intestinal microbiotа leading to its qualitative and quantitative disturbances. The review focuses on the influence of H. pylori and eradication therapy on the content of the intestinal microbiota, their role in the development of intestinal microbiota resistance to antibiotics. Both H. pylori itself and eradication therapy can lead to the changes of gut microbiota content, which are characterized by reduction in microorganisms diversity; decrease in the number of obligate anaerobes, prevailing in normal gut; increase in the number of facultative aerobic microorganisms. Long-term effect of antibiotic therapy is the development of antibiotic-resistant strains of bacteria. Resistance may be due to the presence of the resistance genes in bacteria, which they have acquired through mutations or horizontal transfer. These genes can be spread not only among pathogenic bacteria, due to the presence of which antibacterial therapy is carried out, but also among the members of the normal microflora, which can then be modified and loose its beneficial properties. Thus the intestinal microflora may serve as a potential reservoir of resistance genes and contribute to the development of antibiotics resistance through other members of the human microbiota.